Assessment of the safety and effects on the body of investigational products when used on psoriatic skin

2025-522446-51-00 Protocol BAP5191-102 Human pharmacology (Phase I) - Other Ended

Start 17 Oct 2025 · End 31 Mar 2026 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol BAP5191-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 15
Countries 1
Sites 4

Plaque psoriasis

Key facts

Sponsor
Bacoba AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20], Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
17 Oct 2025 → 31 Mar 2026
Decision date (initial)
2025-10-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Plaque psoriasis

VersionLevelCodeTermSystem organ class
20.0 LLT 10071117 Plaque psoriasis 10040785

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bacoba AG

Sponsor organisation
Bacoba AG
Address
Schloss Buonas 1
City
Buonas
Postcode
6343
Country
Switzerland

Scientific contact point

Organisation
Bacoba AG
Contact name
Quality and Regulatory Affairs Manager

Public contact point

Organisation
Bacoba AG
Contact name
Quality and Regulatory Affairs Manager

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 15 4
Rest of world 0

Investigational sites

Germany

4 sites · Ended
Dr. Niesmann And Dr. Othlinghaus GbR
NA, Alleestrasse 80, Innenstadt, Bochum
SRH Wald-Klinikum Gera GmbH
Zentrum für Klinische Studien, Strasse Des Friedens 122, Debschwitz, Gera
Eurofins bioskin GmbH
Research Center dermatology, Messberg 4, Hamburg-Altstadt, Hamburg
Klinische Forschung Dresden GmbH
NA, Prager Strasse 10, Seevorstadt-Ost/Grosser Garten, Dresden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-10-17 2026-03-30 2025-11-10 2026-03-16

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-11 Germany Acceptable
2025-10-09
2025-10-09
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-27 Germany Acceptable
2025-10-09
2026-03-27